These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6581755)

  • 41. Intramuscular imipenem/cilastatin for treatment of mild and moderately severe bacterial infections.
    Keller CA; Villavicencio J; Ramirez C
    Scand J Infect Dis Suppl; 1987; 52():26-31. PubMed ID: 3483287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative trial of moxalactam plus ticarcillin and clavulanic acid or piperacillin as empiric antibiotic therapy for febrile cancer patients.
    D'Olimpio JT; Miller M; Sheridan CA; Carlisle P; Wollner DI; McKitrick JC; Wiernik PH
    J Clin Pharmacol; 1987 Sep; 27(9):673-7. PubMed ID: 3316311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.
    Norrby SR; Alestig K; Björnegård B; Burman LA; Ferber F; Huber JL; Jones KH; Kahan FM; Kahan JS; Kropp H; Meisinger MA; Sundelof JG
    Antimicrob Agents Chemother; 1983 Feb; 23(2):300-7. PubMed ID: 6573157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postantibiotic effect of imipenem on Pseudomonas aeruginosa.
    Bustamante CI; Drusano GL; Tatem BA; Standiford HC
    Antimicrob Agents Chemother; 1984 Nov; 26(5):678-82. PubMed ID: 6440477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of neutropenic infection: a randomized trial comparing latamoxef (moxalactam) with cephradine plus tobramycin.
    Bezwoda WR; Derman DP; Perkins S; Cassel R
    J Antimicrob Chemother; 1985 Feb; 15(2):239-45. PubMed ID: 3884566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of skin and soft tissue infections with imipenem/cilastatin.
    Fass RJ; Freimer EH; McCloskey RV
    Am J Med; 1985 Jun; 78(6A):110-2. PubMed ID: 3890532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical efficacy, safety and tolerability of intramuscular imipenem/cilastatin in the treatment of mild to moderate infections.
    Garau J; Casagrán A; Sánchez C; Matas E
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():181-3. PubMed ID: 3469192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primaxin in the treatment of acute bacterial pneumonia in adults.
    Gebhart RJ; Duma RJ; Patterson PM; Bagett JW; Williams DS
    J Antimicrob Chemother; 1985 Feb; 15(2):233-8. PubMed ID: 3980311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imipenem in the treatment of severe bacterial infections in seriously ill patients.
    Garau J; Martín R; Bouza E; Romero J; García Rodríguez JA; Perea E; Martínez Luengas F; Gobernado M; Montero R
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():131-40. PubMed ID: 3469185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The activity of N-formimidoyl thienamycin (MK0787) against Haemophilus influenzae and Streptococcus pneumoniae.
    Howard AJ; Hince CJ
    J Antimicrob Chemother; 1982 Nov; 10(5):383-90. PubMed ID: 6983523
    [No Abstract]   [Full Text] [Related]  

  • 54. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imipenem: the first thienamycin antibiotic.
    Geddes AM; Stille W
    Rev Infect Dis; 1985; 7 Suppl 3():S353-6. PubMed ID: 3863216
    [No Abstract]   [Full Text] [Related]  

  • 56. Enterococcal infections in patients treated with moxalactam.
    Moellering RC
    Rev Infect Dis; 1982; 4 Suppl():S708-11. PubMed ID: 6218588
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imipenem/cilastatin for pediatric infections in hospitalized patients.
    Nalin DR; Hart CB; Shih WJ; Aziz MA
    Scand J Infect Dis Suppl; 1987; 52():56-64. PubMed ID: 3331043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imipenem/cilastatin: a multicentre international study of its clinical efficacy, safety and potential as empirical therapy.
    Wang C; Pappas F; Cook T
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():185-91. PubMed ID: 3469193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections.
    Siebert WT; Kopp PE
    Am J Med; 1985 Nov; 79(5B):141-5. PubMed ID: 4073082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open trial of imipenem/cilastatin therapy for serious bacterial infections.
    Brooks RG; McCabe RE; Vosti KL; Remington JS
    Rev Infect Dis; 1985; 7 Suppl 3():S496-505. PubMed ID: 3901213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.